From the research and development strength of the market, look at the future core competitiveness of pharmaceutical companies in the market.

Pharmaceutical Network Industry Dynamics: If the pharmaceutical industry, if operating income, net profit and other indicators reflect the profitability of enterprises at this stage, then research and development investment for pharmaceutical companies to a certain extent reflects the company's strategic planning and the company's future market core competitiveness.
up to now, the domestic listed pharmaceutical companies in 2019 annual report disclosure work has been basically completed, the author according to the company's annual report collated out of the research and development investment data, to take stock of the research and development investment in the top five pharmaceutical companies.
Hengrui Pharmaceuticals: 3.896 billion yuan Hengrui Pharmaceuticals 2019 full-year revenue of 23.289 billion yuan, net profit attributed to the mother 5.328 billion yuan, non-returned net profit of 4,979 million yuan;
, in addition to revenue growth, the highest since 2008, the full year 2019 research and development costs also reached 3.896 billion yuan, the scale and ratio are at a record high.
thanks to a strong investment in research and development, hengrui Pharma continues to launch new drugs.
2019, Hengrui Pharmaceuticals submitted 131 new domestic patent applications, 63 new applications for international PCT, 38 domestic authorizations and 53 foreign authorizations.
the same period, Hengrui Pharmaceuticals obtained 2 batches of innovative pharmaceutical preparations, 11 batch of generic pharmaceutical preparations, 29 clinical batches of innovative drugs, 2 clinical batches of generic drugs.
obtained the approval of the consistency evaluation of 2 varieties and completed the consistent evaluation and declaration of 8 products. In addition to
, Hengrui Pharmaceuticals has also undertaken 44 "national major new drug creation" special projects, has applied for 874 invention patents, of which 335 international patent applications.
Fosun Pharma: 3.463 billion yuan Fosun Pharma's main business is the research and development, production and sales of pharmaceuticals, medical devices and medical diagnostics, as well as medical services as the main body, and through the Group's investment enterprise, State Pharmaceutical Holdings covers the field of pharmaceutical commercial circulation.
While earnings growth has not been stable in recent years, Fosun Pharma has spared no effort in investing in research and development.
2019, Fosun Pharma invested 3,463 million yuan in research and development for the full year, up 38.15 percent year-on-year, accounting for 12.12 percent of total revenue.
, the pharmaceutical business investment in research and development was RMB3.131 billion, an increase of 39.12%, accounting for 14.38% of the pharmaceutical business revenue ratio.
research and development investment continues to move towards international innovative pharmaceutical companies.
From the results of innovative drugs, by the end of 2019, Fosun Pharma has 9 small molecule innovative pharmaceutical products, 9 indications approved by clinical trials in China; in addition to
, in the first half of 2020, Fosun Pharma has also welcomed a number of innovations: the approval of new production capacity of the lithoxide, in 2020 is expected to usher in the release; Clinically approved for listing, which is expected to contribute revenue this year, and qutozumab biosimilars are expected to be approved for listing in the second quarter of 2020, and their listing process in the European Union is expected to reach the forth in 2020, or become the first domestic ally biosimilar drug species to go overseas.
Meirui Medical: 1.649 billion yuan Meirui Medical is mainly engaged in medical device research and development, manufacturing, marketing and services, products covering biological information and support, in vitro diagnosis and medical imaging three major collar.
in recent years, Meirui Medical has continuously increased its research and development investment, exceeding 1 billion yuan in 2016, reaching 1,132 million yuan in 2017, accounting for 10.13 percent of revenue, while in 2019, its research and development investment amounted to 1.649 billion yuan, up 16.15 percent year-on-year, and the proportion of research and development investment in total operating income was 9.96 percent.
at present, Meirui Medical has established a research and development innovation platform based on global resource allocation, with eight research and development centers in Shenzhen, Nanjing, Beijing, Xi'an, Chengdu, Silicon Valley, New Jersey and Seattle, USA, while the ninth research and development center, Wuhan Research Institute, is also under construction.
the future, Murray Medical will continue to ensure investment in research and development, and constantly enhance the strength of global research and development, learn from some of the successful alternative experience in the sub-sector, the focus of layout has not yet achieved replacement of high-end imaging equipment, in vitro diagnostic products and other fields.
Shanghai Pharma: 1,509 million yuan Shanghai Pharma's 2019 annual report shows that its total annual research and development investment totaled 1.509 billion yuan, of which 1.35 0 billion yuan was spent, an increase of 27.22 percent year-on-year.
in fact, in recent years, Shanghai medicine hard work, on the one hand to build a professional marketing system, on the other hand, focus on the focus of specialized efforts.
, the number of products in the cardiovascular, immunomodulative and anti-tumor, systemic anti-infection, respiratory, digestive tract and metabolism of large varieties has grown in size through innovation companies, with the number of products increasing from 31 in 2018 to 35, of which more than 500 million have increased to 9 and 1 billion varieties.
it is worth mentioning that the current Shanghai Pharma using the "independent research and development of the two-legged walking strategy of BD".
in the cost of independent research and development, 34.13% of the cost of innovative drug research and development, and achieved more phased progress.
SPH3127 completed the clinical phase II in one year of all patients into the group, is about to enter the clinical phase III, at the same time the drug has started two new indications of exploration research;
Colum Pharmaceuticals: 1.351 billion yuan has been, Collon Pharmaceuticals has followed the policy-oriented, with a high degree of strategic determination to adhere to the "three-shot drive, innovative growth" strategy, with "hard work, embrace change" as the work guide, adjust the strategy to actively respond to market competition, innovation to promote the company to achieve steady and healthy development.
in 2019, Collum Pharmaceuticals also continued to increase its investment in research and development, according to the annual report, The research and development investment of Collum Pharmaceuticals was 1.351 billion yuan, up 21.24 percent year-on-year, and research and development investment accounted for 7.66 percent of sales revenue.
achieved 13 generic drug approvals and multiple clinical declarations throughout the year, strongly supporting the company's project research and development and innovative development.
in fact, as early as the end of 2012, Collum Pharmaceuticals initiated an innovation transformation, continuing to focus on addressing China's unmet clinical needs and availability of clinical drugs, and continuously promoting the internationalization of innovative drug research, production and listing.
over the years, Curran has initiated research on nearly 500 drugs for domestic and foreign markets around the global and China's unmet clinical needs, new disease targets and new technologies, including 364 generic drugs with cluster, difficulty, characteristics and cost advantages (including consistency evaluation varieties) and 22 improved innovative drugs, 49 innovative small molecules with me-better advantages, and 47 biotechnology drugs.
.